WO2023206985 - ROR1 ANTIBODY OR ROR1 /CD19 /CD3 TRI-SPECIFIC ANTIBODY FOR THE TREATMENT OF TUMORS
National phase entry:
Publication Number
WO/2023/206985
Publication Date
02.11.2023
International Application No.
PCT/CN2022/125623
International Filing Date
17.10.2022
Title **
[English]
ROR1 ANTIBODY OR ROR1 /CD19 /CD3 TRI-SPECIFIC ANTIBODY FOR THE TREATMENT OF TUMORS
[French]
ANTICORPS ROR1 OU ANTICORPS TRI-SPÉCIFIQUE ROR1/CD19/CD3 POUR LE TRAITEMENT DE TUMEURS
Applicants **
SHANDONG BOAN BIOTECHNOLOGY CO., LTD.
PENG Xuerui
IP Department Xuerui PENG
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
BOAN BOSTON LLC
PENG Xuerui
IP Department
19 Presidential Way
Woburn, Massachusetts 01801, US
NANJING BOAN BIOTECH CO. LTD
PENG Xuerui
IP Department
No. 28, Gaoxin Road, Jiangbei New District
Nanjing, Jiangsu 210031, CN
Inventors
WANG, Shuo
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
SONG, Deyong
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
DOU, Changlin
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
ZONG, Mengqi
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
JIAO, Jie
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
FENG, Jianxia
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
KAI, Xin
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
DANIELLA, Tatang
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
ZHANG, Yanan
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
DONG, Chuangchuang
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
Priority Data
202210425699.0
29.04.2022
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1206 | |
| EPO | Filing, Examination | 6907 | |
| Japan | Filing | 592 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 5710 |
Total: 14989 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present application provides an antibody or antigen binding fragment that binds to ROR1 or a variant thereof, and a multi-specific protein molecule (e.g. ROR1 /CD19 /CD3 tri-specific antibody) for the treatment of tumors with high expression of Receptor tyrosine kinase-like orphan receptor 1 (ROR1) or both Receptor tyrosine kinase-like orphan receptor 1 (ROR1) and CD19.[French]
La présente demande concerne un anticorps ou un fragment de liaison à l'antigène qui se lie à ROR1 ou un variant de celui-ci, et une molécule de protéine multi-spécifique (par exemple, un anticorps tri-spécifique ROR1/CD19/CD3) pour le traitement de tumeurs avec une expression élevée du récepteur orphelin 1 de type tyrosine kinase (ROR1) ou du récepteur 1 orphelin de type tyrosine kinase de récepteur (ROR1) et CD19.